Julia Rotow

9PUBLICATIONS
170CO-AUTHORS
Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Oct 14, 2026
Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registry.

|Jul 14, 2026
Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer Receiving First-line Osimertinib.

|Jul 06, 2026
Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.

|May 18, 2026
Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco.

|Apr 07, 2026
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry.

Arianna Marinello, Julia K Rotow, Meghanne Lomibao

|Jan 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.

Sarah Waliany, Alissa J Cooper, Stephen V Liu

Pageof 2

Frequent Collaborators

5 joint publications

Biagio Ricciuti

5 joint publications

Mihaela Aldea

4 joint publications

Alexander Drilon

4 joint publications

Andrea De Giglio